You are here:
Publication details
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
Authors | |
---|---|
Year of publication | 2024 |
Type | Article in Periodical |
Magazine / Source | EUROSURVEILLANCE |
MU Faculty or unit | |
Citation | |
Web | https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.3.2300708#abstract_content |
Doi | http://dx.doi.org/10.2807/1560-7917.ES.2024.29.3.2300708 |
Keywords | bivalent mRNA COVID-19 vaccines;Omicron XBB lineage-predominant period;VEBIS SARI VE network |
Description | We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged???60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated >?6 months before the campaign: from 80% (95%?CI: 50?to?94) for 14–89 days post-vaccination, 15% (95%?CI: -12?to?35) at 90–179 days, and lower to no effect thereafter. |